Genetic approach to thrombophilia

Thrombosis and Haemostasis

Volumn 86, Issue 1, 2001, Pages 92-103

  Bertina, R M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Genetic risk factors; Polymorphisms; Thrombophilia; Venous thrombosis

Indexed keywords

PROTEIN C; PROTEIN S;

CONFERENCE PAPER; ENVIRONMENTAL FACTOR; FAMILIAL DISEASE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC POLYMORPHISM; HEMOSTASIS; HUMAN; MOLECULAR INTERACTION; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; THROMBOPHILIA; VEIN THROMBOSIS;

EID: 0034924221     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1616205     Document Type: Conference Paper

References (198)

1. Inherited thrombophilia: Part I
2. Venous thrombosis: A multicausal disease
3. Molecular risk factors for thrombosis
4. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis
5. Inherited antithrombin III deficiency causing thrombophilia
6. Deficiency of protein C in congenital thrombotic desease
7. Familial protein S deficiency is associated with recurrent thrombosis
8. Inherited fibrinogen abnormality causing thrombophilia
9. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C
10. Mutation in blood coagulation factor V associated with resistance to activated protein C
11. Venous thromboembolic disease and ABO blood type
12. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis
13. Inherited predisposition to thrombosis
14. Activated protein C resistance as an additional risk factor for thrombosis in protein C deficient families
15. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S
16. Factor V Leiden (F V R506Q) in families with inherited antithrombin deficiency
17. Factor V Leiden: An additional risk factor for thrombosis in protein S deficient families
18. Thrombophilia as a multigenic disorder
19. Familial thrombophilia: A complex genetic disorder
20. Prevalence of heriditary thrombophilia and the identification of genetic risk factors
21. Antitrombin III deficiency and thromboembolism
22. Antithrombin and its inherited deficiency states
23. Hereditary protein C deficiency
24. The spectrum of genetic defects in a panel of 40 Dutch families with symptomatic protein C deficiency type I: Heterogeneity and founder effects
25. Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect
26. Hereditary protein S deficiency: Clinical manifestations
27. Three novel mutations in five unrelated subjects with hereditary protein S deficiency type I
28. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype
29. Association of the R 455 K polymorphism of the factor V gene with poor response to activated protein C and increased risk of coronary artery disease in the Chinese population
30. A reduced sensitivity for activated protein C in the absence of factor V Leiden, increases the risk of venous thrombosis
31. Hyperhomycosteinemia as a risk factor for deep-vein thrombosis
32. Role of clotting factor VIII in effects of von Willebrand factor on occurrence of deep-vein thrombosis
33. High levels of coagulation factor XI as a risk factor for venous thrombosis
34. High levels of factor IX increase the risk of venous thrombosis
35. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis
36. Will genetics revolutionize medicine
37. Duration of anticoagulants in acute or recurrent venous thromboembolism
38. Duration of oral anticoagulant treatment in patients with venous thromboembolism and a deficiency of antithrombin, protein C or protein S - A decision analysis
39. Screening tests for thrombophilic patients. Which test for which patient, by whom, when and why?
40. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9
41. Genetic association between sensitivity to warfarin and expression of CYP2C9*3
42. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
43. A mutation in the propeptide of factor IX leads to warfarin sensitivity by a novel mechanism
44. Missense mutations at ALA-10 in the factor IX propeptide: An insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy
45. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C
46. Antithrombin mutation database: First update
47. Protein C deficiency a database of mutations, 1995 update
48. Protein S deficiency: A database of mutations - Summary of the first update
49. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis
50. Apparent different thrombotic tendency in patients with factor V Leiden and protein C deficiency due to selection in patients
51. Co-inheritance of the 20210A allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia
52. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation
53. Absence of thrombosis in subjects with heterozygous protein C deficiency
54. Prevalence of protein C deficiency in the healthy population
55. Venous thromboembolism associated with double heterozygosity for R506Q mutation of factor V and for T298M mutation of protein C in a large family of a previously described homozygous protein C-deficient newborn with massive thrombosis
56. The prothrombin 20210 G to A variation and thrombosis
57. The G20210A prothrombin polymorphism is not associated with increased thromboembolic risk in a large protein C deficient kindred
58. Protein C deficiency and venous thrombosis - The search for the second genetic defect
59. Coinheritance of the HR2 haplotype in the factor V gene confers an increased risk of venous thromboembolism to carriers of factor V R506Q
60. Pseudo-homozygous activated protein C resistance due to coinheritance of heterozygous factor V-R506Q and type I factor V deficiency associated with thrombosis
61. "Pseudohomozygous" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: Report of two cases belonging to two unrelated kinreds
62. Recurrent thrombosis due to compound heterozygosity for factor V Leiden and factor V deficiency
63. Molecular characterization of a type I quantitative factor V deficiency in a thrombosis patient that is "Pseudo homozygous" for activated protein C resistance
64. Characterization of single-nucleotide polymorphisms in coding regions of human genes
65. Sequence diversity in 36 candadate genes for cardiovascular disorders
66. Association studies of genetic polymorphisms and complex disease
67. Genetic dissection of complex traits
68. Searching for genes in complex diseases: Lessons from systemic lupus erythematosus
69. The future of genetic studies of complex human diseases
70. The first mutation identified in the thrombomodulin gene in a 45-year old man presenting with thromboembolic disease
71. Thrombomodulin gene defects in families with thromboembolic disease - A report on four families
72. The G1456 to T mutation in the thrombomodulin gene is not frequent in patients with venous thrombosis
73. A mutation in the thrombomodulin gene, 127 G to A, coding for Ala 25 Thr and the risk of myocardial infarction in men
74. Thrombomodulin gene mutations associated with myocardial infarction
75. Prothrombin and the prothrombin 20210G to A polymorphism: Their relationship with hypercoagulability and thrombosis
76. The prothrombin gene variant 20210A in venous and atherial thromboembolism
77. G2010A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men
78. A single genetic origin for the common prothrombotic G20210A polymorphism in the prothrombin gene
79. Polymorphisms in the prothrombin gene and their association with plasma prothrombin levels
80. Geographical distribution of the prothrombin 20210A G to A prothrombin variant
81. A 23 bp insertion in the endothelial protein C receptor (EPCR) gene in patients with myocardial infarction and deep vein thrombosis
82. The endothelial cell protein C receptor
83. Prospects for whole-genome linkage disequilibrium mapping of common disease genes
84. A polymorphism in the 5′ region of coagulation factor VII gene (F7) caused by an inserted decanucleotide
85. Functional characterization of the human factor VII 5′ flanking region
86. Two common functional polymorphisms in the promoter region of the coagulation factor VII gene determining plasma factor VII activity and mass concentration
87. A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals
88. The Arg 353 Gln polymorphism reduces the level of coagulation factor VII; In vivo and in vitro studies
89. Modulation of factor VII levels by intron 7 polymorphisms: Population and in vitro studies
90. Factor VII gene polymorphisms contribute about one third of the factor VII level variation in plasma
91. Genetic epidemiology of single-nucleotide polymorphisms
92. Role of hemostatic gene polymorphisms in venous and arterial thrombosis
93. Hyperhomocysteinemia, atherosclerosis and thrombosis
94. Thermolabile methylenetetrahydrofolate reductase and factor V Leiden in the risk of deep-vein thrombosis
95. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance)
96. Factor V gene mutation is a risk factor for cerebral vein thrombosis
97. Genetic risk factors for superficial vein thrombosis
98. Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis
99. Low prevalence of factor V:Q506 in 41 patients with isolated pulmonary embolism
100. Activated protein C resistance, factor V Leiden and retinal vessel occlusion
101. Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation
102. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis
103. Female gender and resistance to activated protein C (FV:Q506) as potential risk factors for thrombosis after elective hip arthroplasty
104. Deletion polymorphism in the angiotensin-converting enzyme gene as a thrombophilic risk factor after hip arthroplasty
105. Relation of three genetic traits to venous thrombosis in a African-American population
106. Moderation of Hemophilia A phenotype by the factor V R506Q mutation
107. Effect of factor V Leiden mutation on the clinical expression of severe hemophilia A
108. Location on the human genetic linkage map of 26 genes involved in blood coagulation
109. Genetic screening of candidate genes for a prothrombotic interaction with type I protein C deficiency in a large kindred
110. Genetic determinants of hemostasis phenotypes in Spanish families
111. The genetics of haemostasis: A twin study
112. Heritability of elevated factor VIII antigen levels in factor V Leiden families with thrombophilia
113. Familial clustering of factor VIII and von Willebrand factor levels
114. The VITA project: Heritability of resistance to activated protein C
115. Linkage analysis demonstrates that the prothrombin G20210A mutation jointly influences plasma prothrombin levels and risk of thrombosis
116. Multipoint quantitative-trait linkage analysis in general pedigrees
117. Joint multipoint linkage. Analysis of multivariate qualitative and quantitative traints I. Likehood formulation and simulation results
118. Functional effects of the ABO locus polymorphism on plasma levels of von Willebrand factor, factor VIII and activated partial thromboplastin time
119. Genetic susceptibility to thrombosis and its relationship to physiological risk factors: The GAIT study
120. The clinical spectrum of heterozygous protein C deficiency in a large New England kindred
121. Genetic analysis of a large kindred exhibiting type I protein C deficiency and associated thrombosis
122. An unknown genetic defect increases venous thrombosis risk, through interaction with protein C deficiency
123. De TDT and other family based tests for linkage disequilibrium and association
124. Genetic analysis of inherited thrombophilia
125. Linkage studies in familial thrombosis point to the interleukin-1 locus as a candidate susceptibility marker
126. The A20210 allele in the prothrombin gene enhances the risk of venous thrombosis in carriers of inherited protein S deficiency
127. Study of the prothrombin gene 20210 GA variant in FV: Q506 carriers in relationship to the presence or absence of juvenile venous thromboembolism
128. Protein C deficiency in a controlled series of unselected outpatients: An infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study)
129. Factor V Leiden and other coagulation risk factor mutations affecting thrombotic risk
130. Polymorphisms in the 5′ regulatory region of the tissue factor gene and the risk of myocardial infarction and venous thromboembolism: The ECTIM and PATHROS studies
131. Factor VII coagulant activity and antigen levels in healthy men are determined by interaction between factor VII genotype and plasma triglyceride concentration
132. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms. The Leiden Thrombophilia Study (LETS)
133. Factor X levels, polymorphisms in the promoter region of factor X, and the risk of venous thrombosis
134. A genetic variant in the promoter of coagulation factor X increases the risk of acute coronary syndromes
135. A common genetic polymorphism (46C to T substitution) in the 5'-untranslated region of the coagulation factor XII gene is associated with low translation efficiency and decrease in plasma factor XII level
136. Polymorphism in exon 10 of the human coagulation factor V gene in a population at risk for sickle cell disease
137. A polymorphism nt 1628 G → A (R485K) in exon 10 of the coagulation factor V gene may be a risk factor for thrombosis in the indigenous Thai population
138. The factor V R2 allele: Risk of venous thromboembolism, factor V levels and resistance to activated protein C
139. The factor V gene A4070G mutation and the risk of venous thrombosis
140. Detection of new polymorphic markers in the factor V gene: Association with factor V levels in plasma
141. Mutation in the R2 FV gene affect the ratio between the two FV isoforms in plasma
142. Variation at the von Willebrand factor (vWF) gene locus is associated with plasma vWF: Ag levels: Identification of three novel single nucleotide polymorphisms in the vWF gene promoter
143. High factor VIII antigen levels increase the risk of venous thrombosis but are not associated with polymorphisms in the von Willebrand factor and factor VIII gene
144. Alpha-fibrinogen Thr 312 Ala polymorphism and venous thromboembolism
145. Human fibrinogen polymorphic site analysis by restriction endonuclease digestion and allele-specific polymerase chain reaction amplification: Identification of polymorphisms at position A312 and B448
146. -455 polymorphism, age and smoking
147. β-fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction (the ECTIM study)
148. Bcl I polymorphism in the fibrinogen beta-chain gene is associated with the risk of familial myocardial infarction by increasing plasma fibrinogen levels. A case-control study in a sample of Gissi-2 patients
149. The FXIII Val 34 Leu polymorphism in venous and arterial thrombosis
150. Association of a common polymorphism in the factor XIII gene with venous thrombosis
151. Prothrombin G20210A, factor V Leiden and factor XIII Val 34 Leu: Common mutations of blood coagulation factors and deep vein thrombosis in Austria
152. Deficiency in the A subunit of coagulation factor XIII: Two novel point mutations demonstrate different effects on transcript levels
153. Factor XIII Val 34 Leu polymorphism and risk of deep venous thrombosis
154. Factor XIII Val 34 Leu is a genetic factor involved in the etiology of venous thrombosis
155. The Val 34 Leu mutation and the risk of venous thrombosis
156. Val 34 Leu polymorphism of plasma factor XIII: Biochemistry and epidemiology in familial thrombophilia
157. The factor XIII Val 34 Leu polymorphism accelerates thrombin activation of factor XIII and effects crosslinked fibrin structure
158. Effect of Val 34 Leu polymorphism on the activation of the coagulation factor XIII
159. A common polymorphism in the FXIIIA subunit gene (FXIII Val 34 Leu) affects cross-linking activity
160. Factor XIII Val 34 Leu, factor XIII antigen levels and activity and the risk of deep venous thrombosis
161. Identification of polymorphisms in the TAFI gene promoter: Relationship with plasma TAFI levels and risk of venous thrombosis
162. Genotypic variation in the promoter region of the protein C gene is associated with plasma protein C levels and thrombotic risk
163. Complex association of protein C gene promoter polymorphism with circulating protein C levels and thrombotic risk
164. Polymorphic variation in the human protein C (PROC C) gene promoter can influence transcriptional efficiency in vitro
165. A CCA/CCG neutral polymorphism in the codon for Pro 626 in the human protein S gene PS alpha (PROS1)
166. Influence of the nt 2148 A to G substitution (Pro 626 dimorphism) in the PROS1 gene on circulating free PS levels in healthy volunteers - Reappraisal of protein S normal ranges
167. Genetic modulation of plasma protein S levels by two frequent dimorphisms in the PROS1 gene
168. Two new frequent dimorphisms in the protein S (PROS1) gene
169. A frequent thrombomodulin amino acid dimorphism is not associated with thrombophilia
170. The 536 CT transition in the human tissue factor pathway inhibitor (TFPI) gene is statistically associated with a higher risk of venous thrombosis
171. C-399T polymorphism in the promoter region of human tissue factor pathway inhibitor (TFPI) gene does not change the plasma TFPI antigen level and does not cause venous thrombosis
172. No link between the TFPI V264M mutation and venous thromboembolic disease
173. The C536T transition in the tissue factor pathway inhibitor (TFPI) gene does not contribute to risk of venous thrombosis among carriers of factor V Leiden
174. A new T-278C polymorphism in the 5' regulatory region of the tissue factor pathway inhibitor gene association study of the T-287C and C-399T polymorphisms with coronary artery disease and plasma TFPI levels
175. Polymorphisms of the tissue factor pathway inhibitor (TFPI) gene in patients with acute coronary syndromes and in healthy subjects: Impact of the V264M substitution on plasma levels of TFPI
176. The TFPI 536CT mutation is not associated with increased risk for venous or arterial thrombosis
177. The C536T transition in the tissue factor pathway inhibitor gene is not a common cause of venus thromboembolic disease in the UK population
178. Allelic dimorphism in the human tissue-type plasminogen activator (TPA) gene as a result of an Alu isertion/deletion event
179. Gene polymorphism of t-PA is associated with forearm vascular release rate of t-PA
180. Identification of eight novel single-nucleotide polymorphisms at human tissue-type plasminogen activator (t-PAI) locus: Association with vascular t-PA release in vivo
181. Alu-repeat polymorphism in the tissue-type plasminogen activator gene does not effect basal endothelial tPA synthesis
182. 4G/5G promoter PAI-1 gene polymorphism is associated with plasmatic PAI-1 activity in Italians: A model of gene environment interaction
183. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in hepG2 cells
184. The A-844G polymorphism in the PAI-1 gene is associated with a higher risk of venous thrombosis in factor V Leiden carriers
185. Effect of plasminogen activator inhibitor-1 4G/5G polymorphism in Turkish deep vein thrombotic patients with and without FV 1691 G-A
186. Moderate genetic influences on plasma levels of plasminogen activator inhibitor-1 and evidence of genetic and environmental influences shared by plasminogen activator-1, triglycerides, and body mass index
187. Genetic variation in the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity
188. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study
189. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor-1 gene is associated with myocardial infarction
190. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohost of US men
191. Five frequent polymorphism of the PAI-1 gene. Lack of association between genotype, PAI-1 activity, and triglyceride levels in a healthy population
192. A novel G/A and the 4G/5G polymorphisms within the promoter of the plasminogen activator inhibitor-1 gene in patients with deep vein thrombosis
193. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: Relationship to plasma PAI-1 level in venous thromboembolism
194. A common 4G allele in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene as a risk factor for pulmonary embolism and arterial thrombosis in hereditary protein S deficiency
195. Protective effect of a thrombin receptor (protease-activated receptor 1) gene polymorphism toward venous thromboembolism
196. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels
197. Epidemiology of factor V Leiden: Clinical implications
198. The HR2 haplotype of factor V: Effects on factor V levels, normalized activated protein C sensitivity ratios and the risk of venous thrombosis